Scholar Rock Holding Corp, Inc.

Scholar Rock Holding Corp. is a U.S. biopharmaceutical company based in Cambridge, Massachusetts, focused on medicines for serious diseases including neuromuscular disorders, cancer and fibrosis. Its lead product candidate, apitegromab, is designed to inhibit myostatin in skeletal muscle.

The company is publicly traded on Nasdaq under the ticker SRRK (SEC file number 001-38501) following an initial public offering in May 2018. As of a November 2024 report, its market capitalization was approximately $2.5 billion at a share price of $27.67. As of a July 2026 Form 144 filing, roughly 119.8 million common shares were outstanding and the registered address was 301 Binney Street, 3rd Floor, Cambridge, Massachusetts.

Business model

Scholar Rock is a clinical-stage biopharmaceutical company; sources describe it as developing product candidates rather than selling approved products, with its lead candidate apitegromab (also referred to in one source as 'Apitegroma') still in development and subject to regulatory review in the U.S., Europe and Japan. No revenue-generating commercial operations are described in the sources.

Traction

Publicly traded since May 2018 with a reported market capitalization of about $2.5 billion as of November 2024 and institutional ownership including Vanguard Group's 4,034,665 shares as of September 30, 2024. The lead candidate apitegromab was the subject of regulatory status updates in the U.S., Europe and Japan.

Latest developments

A July 1, 2026 Form 144 filing disclosed a proposed sale of 2,544 common shares by director Michael Gilman, with an aggregate market value of $139,385, under a Rule 10b5-1 plan adopted March 31, 2026. Related headlines reference updates to apitegromab's regulatory status in the U.S., Europe and Japan and new employee inducement grants made under Nasdaq Listing Rule 5635(c)(4).